BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI) Q4 2019 Results Earnings Conference Call February 18, 2020 8:00 AM ET Company Participants Sean Leous - ICR Westwicke Chaim Lebovits - President and Chief Executive Officer Preetam Shah - EVP and Chief Financial Officer Ralph Kern - Chief Operating and Chief Medical Officer Arturo Araya - Chief Commercial Officer Conference Call Participants Jason Kolbert - Dawson James Operator Greetings and welcome to the BrainStorm Cell Therapeutics Fourth Quarter 2019 Earn ...

UNITED STATES Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.00005 par value BCLI NASDAQ Stock Market LLC (Nasdaq Capital Market) SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K x ANNUAL REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2019 ¨ TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM __________ TO _________ ...

BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI) Q3 2019 Earnings Conference Call November 14, 2019 8:00 AM ET Company Participants Sean Leous – ICR Westwicke Chaim Lebovits – President and Chief Executive Officer Preetam Shah – Chief Financial Officer Ralph Kern – Chief Operating Officer, Chief Medical Officer Arturo Araya – Chief Commercial Officer Conference Call Participants David Bautz – Zacks Small Cap Research Jason Kolbert – Dawson James Jack Mayer – Private Investor Jason McCarthy – Maxim Operator ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________ to _____________ Commission File Number 001-36641 BRAINSTORM CELL THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Dela ...

BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI) Q2 2019 Results Earnings Conference Call August 13, 2019 8:00 AM ET Company Participants Sean Leous - ICR Westwicke Chaim Lebovits - President and Chief Executive Officer Eyal Rubin - Executive Vice President and Chief Financial Officer Ralph Kern - Chief Operating Officer and Chief Medical Officer Conference Call Participants David Bautz - Zacks Small Cap Research Jason Kolbert - Dawson James John Rice - Wells Fargo Operator Good day and welcome to BrainStorm ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.00005 par value BCLI NASDAQ Stock Market LLC (Nasdaq Capital Market) FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period f ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________ to _____________ Commission File Number 001-36641 BRAINSTORM CELL THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K x ANNUAL REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2018 ¨ TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM __________ TO __________ COMMISSION FILE NUMBER 001-36641 BRAINSTORM CELL THERAPEUTICS INC. (Exact Name of Registrant as specified in its charter) Delaware 20-7273918 (State or other jurisd ...